Silodosin Capsule
Product Images NDC 42291-777

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Silodosin (NDC 42291-777). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 (777 30)

Silodosin Capsules 4 mg oral dose packaging label. Contains 30 capsules. Label shows manufacturer as AvKARE and Amneal Pharmaceuticals of NY, LLC. Includes dosage instructions and storage information, with a warning to keep out of reach of children.*

FDA Label Image

90 (778 90)

Silodosin 8 mg capsules label showing the product name and strength prominently. The label indicates each capsule contains 8 mg of Silodosin and is intended for oral use with a usual dosage of one capsule daily with a meal. The label is for a bottle of 90 capsules, manufactured for AvKARE and by Amneal Pharmaceuticals of NY, LLC. Storage instructions and barcode are included, along with NDC number 42291-778-90.*

FDA Label Image

Structure (Silodosin Capsules 1)

Chemical structure of Silodosin, showing its molecular configuration with aromatic rings, amide group, and functional substituents characteristic of this active pharmaceutical ingredient.*

FDA Label Image

As (Silodosin Capsules 2)

A line graph showing Silodosin concentration (ng/mL) in blood plasma over time (hours). The x-axis represents time from 0 to 25 hours, and the y-axis shows Silodosin concentration from 0 to 80 ng/mL. Data points with error bars depict the pharmacokinetic profile, peaking around 4 hours and declining gradually thereafter.*

FDA Label Image

Fg (Silodosin Capsules 3)

Line graph comparing change from baseline in IPSS total score over time between placebo and Silodosin 8 mg. The x-axis represents days, and the y-axis shows the change in score. Silodosin 8 mg demonstrates a greater reduction in IPSS score over the study period than placebo.*

FDA Label Image

Jh (Silodosin Capsules 4)

Line graph depicting the change from baseline in IPSS Total Score over time in days, comparing Placebo and Silodosin 8 mg groups. The graph shows a greater decrease in the IPSS score for Silodosin 8 mg, indicating improved outcomes compared to Placebo, with statistically significant differences noted at specific time points.*

FDA Label Image

Ad (Silodosin Capsules 5)

A line graph depicting the change from baseline in Cmax (mL/sec) over time in days for Silodosin 8 mg and placebo groups. The x-axis represents days with specific intervals, while the y-axis shows the change in Cmax. Data points indicate higher increases for Silodosin compared to placebo, with statistical significance noted at certain time points.*

FDA Label Image

Uy (Silodosin Capsules 6)

A line graph comparing change from baseline in Cmax (mL/sec) over days between Silodosin 8 mg and placebo groups. The graph shows Cmax values on the y-axis and days on the x-axis, indicating higher and sustained Cmax levels in the Silodosin 8 mg group compared to placebo, with statistical significance noted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.